Billionaire Buffett's Berkshire pares drug holdings, sheds Axalta, Biogen


Warren Buffett

NEW YORK: Billionaire Warren Buffett's (pic) Berkshire Hathaway Inc said on Monday it trimmed or eliminated its stakes in several pharmaceutical companies, and reported a small new stake in a Merck & Co spinoff, Organon & Co.

In the second quarter, Berkshire said it exited a $180 million stake in Biogen Inc and reduced investments in Abbvie Inc, Bristol-Myers Squibb Co and Merck.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Country Garden allowed to postpone first payments on three onshore bonds
Thai c.bank says intervenes to ease baht volatility, policy rate 'robust'
Indonesia's central bank delivers surprise rate rise to support rupiah
E-commerce bolsters consumption
The art of branding
ACE Market-bound Farm Price aims to raise RM24.5mil from IPO
PCG to focus on advancing growth initiatives, strengthening operational performance
The bead generation
HSS Engineers declares 1.21 sen dividend on strong FY23 financial performance
Asian FX gain as dollar droops, stocks track Wall Street higher

Others Also Read